PT - JOURNAL ARTICLE AU - THEODOROS ILIAKIS AU - VASILIKI PAPADOPOULOU AU - PANAGIOTIS T. DIAMANTOPOULOS AU - PANAYIOTIS PANAYIOTIDIS AU - KONSTANTINOS ZERVAKIS AU - NEFELI GIANNAKOPOULOU AU - GERASSIMOS TILIMIDOS AU - MARIA ANGELOPOULOU AU - MARINA P. SIAKANTARIS AU - GERASSIMOS PANGALIS AU - MARINA MANTZOURANI AU - ELENI VARIAMI AU - NORA ATHINA VINIOU TI - Cessation of Tyrosine Kinase Inhibitors in Patients with Chronic-phase Chronic Myelogenous Leukemia Following Durable Complete Molecular Response: A Single Center Facing the Dilemma DP - 2013 Aug 01 TA - Anticancer Research PG - 3509--3514 VI - 33 IP - 8 4099 - http://ar.iiarjournals.org/content/33/8/3509.short 4100 - http://ar.iiarjournals.org/content/33/8/3509.full SO - Anticancer Res2013 Aug 01; 33 AB - Tyrosine kinase inhibitors (TKIs), namely imatinib mesylate (IM) and recently approved second-generation TKIs dasatinib and nilotinib, are currently considered the treatment of choice for newly-diagnosed chronic phase chronic myelogenous leukemia (CP-CML). Although treatment with TKIs has not yet been proven curative, it certainly accomplishes a sustained control of the disease in the vast majority of patients. More than a decade after the successful launching of IM in first-line treatment of CP-CML and the subsequent introduction of second-generation TKIs in this setting, the question of the possibility of TKI cessation in a specific subset of patients has emerged. Side-effects of TKIs, along with some patients' wish to abandon the drugs and the rising financial burden upon healthcare systems, have led to the dilemma whether IM can be safely withdrawn after achieving deep molecular remissions and which patients are suitable for this discontinuation. We examined the data of our patients with CML in search of potential canditates for cessation of TKI therapy and identified their characteristics. We also performed a thorough review of the relevant literature. Eight out of fifty patients were discriminated on grounds of sustained complete molecular response (CMR) exceeding 12 months, most of them with a low or intermediate Sokal score at diagnosis. The median interval from IM initiation to CMR was almost 2 years and the median duration of detected CMR reached 6.5 years. Based on the promising results of prospective clinical trials reporting successful cessation of treatment with TKIs on selected subgroups of patients, we decided to proceed to interruption of therapy in the specific subset of our patients and closely monitor their response.